Should women with adequately debulked ovarian cancer receive bevacizumab with chemotherapy in the adjuvant setting?
3 Answers
Mednet Member
Medical Oncology · University of Pittsburgh Magee Womens Hospital
The answer to this question is definitively NO.
Two large, definitive studies (ICON-7 and GOG218 – including over 3400 patient combined) evaluated the impact of adjuvant chemotherapy with concurrent + maintenance bevacizumab. Analysis of mature data from ICON-7 demonstrated a significant overall surv...
Mednet Member
Medical Oncology · The Oncology Institute of Hope and Innovation
For women with optimally cytoreduced disease
In GOG 252: All treatment arms also received bevacizumab- the effect of the addition of bevacizumab is unknown. We await data on the subset of patients for whom a complete surgical resection was pathologically confirmed, as this group of patients had hist...
Mednet Member
Gynecologic Oncology · Tulane University School of Medicine
I have been offering Bevacizumab as maintenance, based on the GOG 218 data, with the caveat that it depends on BRCA testing. If the patient has either a germline or somatic BRCA mutation, then I would use olaparib as maintenance instead of bev.